(MENAFN- News Direct) Exton, PA | October 12, 2021 07:56 AM Eastern Daylight Time
US Digestive Health, a management services organization created to expand access to high-quality, value-based gastroenterology care, began a trial with GI Genius, a state-of-the-art AI-enhanced endoscopy aid device for the detection of colorectal lesions during colonoscopy.
GI Genius utilizes artificial intelligence to improve detection of colorectal cancer during screening colonoscopy procedures. Medtronic received approval from the FDA in April of this year. US Digestive health initiated a trial of the new technology in July 2021 and is the first practice in Pennsylvania to offer GI Genius.
“We are constantly researching and investing in ways to help our providers detect potentially cancerous lesions,” said Dr. Dale Whitebloom, Chief Medical Officer of US Digestive Health.“We want the very best for our patients and if AI helps us to detect cancerous and precancerous lesions more effectively then we want to explore it thoroughly.”
GI Genius is a combination of hardware and software that helps identify regions of interest during the colonoscopy. The device is not intended to replace lab sampling or suggest a course of action to the physician – but it does aid in highlighting areas of concern for providers to address.
“US Digestive Health is committed to bringing the latest advances in colorectal cancer screening to our communities,” said Jerry Tillinger, CEO of US Digestive Health.“We are proud to be the first practice in Pennsylvania to deploy this incredible technology for our patients.”
With offices throughout Central and Southeastern Pennsylvania, including the Greater Philadelphia region, US Digestive Health works hand-in-hand with gastroenterology partner practices to meet the challenges of a fast-changing healthcare landscape. By providing innovative business management and technology solutions that ease administrative burdens and support their financial success, US Digestive Health allows physicians to stay focused on delivering great patient care.
US Digestive Health was formed in 2019 by Amulet Capital Partners, LP (“Amulet”), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians.
For more information, visit
About US Digestive Health
As the leading gastroenterology practice on the East Coast, US Digestive Health is at the forefront of the rapidly advancing science of digestive health, bringing new insight into the care, treatment and prevention of digestive health disorders. For more information, visit
About Amulet Capital Partners, LP
Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit Media Contact for Amulet Capital Partners, LP
Melissa Sheer
Kent Place Communications, LLC
917-690-2199
MENAFN13102021005728012573ID1102960716
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.